Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis

Peter J. Krause, Paul G. Auwaerter, Raveendhara R. Bannuru, John A. Branda, Yngve T. Falck-Ytter, Paul M. Lantos, Valéry Lavergne, H. Cody Meissner, Mikala C. Osani, Jane Glazer Rips, Sunil K. Sood, Edouard Vannier, Elizaveta E. Vaysbrot, Gary P. Wormser

Research output: Contribution to journalReview articlepeer-review

Abstract

The purpose of this guideline is to provide evidence-based guidance for the most effective strategies for the diagnosis and management of babesiosis. The diagnosis and treatment of co-infection with babesiosis and Lyme disease will be addressed in a separate Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) guideline [1]. Recommendations for the diagnosis and treatment of human granulocytic anaplasmosis can be found in the recent rickettsial disease guideline developed by the Centers for Disease Control and Prevention [2]. The target audience for the babesiosis guideline includes primary care physicians and specialists caring for this condition, such as infectious diseases specialists, emergency physicians, intensivists, internists, pediatricians, hematologists, and transfusion medicine specialists.

Original languageEnglish (US)
Pages (from-to)185-189
Number of pages5
JournalClinical Infectious Diseases
Volume72
Issue number2
DOIs
StatePublished - Jan 15 2021

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis'. Together they form a unique fingerprint.

Cite this